Advances in the pharmacological management of breathlessness

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 2, 2009, Pages 103-106

  Currow, David C ^a   Ward, Alicia M ^b   Abernethy, Amy P ^a,c  

^a FLINDERS UNIVERSITY   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dyspnea; Dyspnea drug therapy; Frusemide; Morphine; Palliative care

Indexed keywords

FUROSEMIDE; LOOP DIURETIC AGENT; MORPHINE; NARCOTIC AGENT;

ARTICLE; DYSPNEA; HUMAN; NEBULIZER; PALLIATIVE THERAPY;

DYSPNEA; FUROSEMIDE; HUMANS; MORPHINE; NARCOTICS; NEBULIZERS AND VAPORIZERS; PALLIATIVE CARE; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 67651202399     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32832b37fa     Document Type: Article

References (29)

1. Bredin M, Corner J, Krishnasamy M, et al. Multicenter randomized controlled trial of nursing intervention for breathlessness in patients with lung cancer. Br Med J 1999;318:901-904.
2. Corner J, Plant H, A'Hern R, Bailey C. Nonpharmacological intervention for breathlessness in lung cancer. Palliat Med 1996;10:299-305.
3. Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002;88:1500-1511.
4. Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Resp Care 2007;52:900-910.
5. Bailey PL, Lu JK, Pace NL, et al. Effects of intrathecal morphine on the ventilatory response to hypoxia. N Engl J Med 2000;343:1228-1234.
6. Pattinson KTS. Opioids and the control of respiration. Br J Anaesth 2008;100:747-758.
7. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-944.
8. Abernethy AP, Currow DC, Frith P, et al. Randomised double-blind placebocontrolled crossover trial of sustained-release morphine for the management of refractory dyspnoea. Br Med J 2003;327:523-525.
9. Clemens KE, Klaschik E. Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 2007;33:473-481.
10. Global Initiative for Chronic Obstructive Lung Disease. 2006 Edition. www.goldcopd.org. [Accessed 28 January 2008]
11. Kvale PA, Selecky PA, Prakash UBS. Palliative care in lung cancer. Chest 2007;132:368S-403S.
12. Ben-Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26:2396-2404. A comprehensive review of the current evidence for the treatment of dyspnoea in cancer.
13. Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002;4:753-756.
14. Currow DC, Plummer J, Frith P, Abernethy AP. Can we predict which patients with refractory dyspnea will respond to opioids? J Pall Med 2007;10:1031-1036.
15. Viola R, Kiteley C, Lloyd NS, et al. The management of dyspnea in cancer patients: a systematic review. Support Care Cancer 2008;16:329-337. A useful overview of the approaches to breathlessness in people with cancer. The review includes pharmacological and nonpharmacological approaches.
16. Clemens KE, Klaschik E. Effect of hydromorphone on ventilation in palliative care patients with dyspnoea. Support Care Cancer 2008;16:93-99.
17. Estfan B, Mahmoud F, Shaheen P, et al. Respiratory function during parenteral opioid titration for cancer pain. Pall Med 2007;21:81-86.
18. Currow DC. The pharmacological management of dyspnoea. In: Booth S, Dudgeon D, editors. Dyspnoea. Oxford: Oxford University Press; 2005.
19. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009;65:121-139.
20. Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Resp Phys Neurobiol 2007;156:1-8. An overview of a subtype of breathlessness that can be created in the laboratory with significant clinical correlations.
21. Newton PJ, Davidson PM, Macdonald P, et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008;36:424-441. An excellent overview of the uses of frusemide beyond diuresis for breathlessness. Much of the paper reviews asthma, but six papers relate predominantly to breathlessness.
22. Bianco S, Pieroni MG, Refini RM, et al. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Eng J Med 1989;321:1069-1073.
23. Ong KC, Kor AC, Chong WF, et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1028-1033.
24. Kohara H, Ueoka H, Aoe K, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003;26:962-967.
25. Shimoyama N, Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002;23:73-76.
26. Stone P, Rix E, Kurowska A, Tookman A. Nebulized furosemide for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002;24:274-275.
27. Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000;161:1963-1967.
28. Minowa Y, Ide T, Nishino T. Effects of inhaled furosemide on CO2 ventilatory responsiveness in humans. Pulm Pharmacol Ther 2002;154:363-368.
29. Harver A, Mahler DA, Schwartzstein RM, Baird JC. Descriptors of breathlessness in healthy individuals: distinct and separable constructs. Chest 2000;118:679-690.